These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28431640)

  • 1. Rapid Assessment of Drugs of Abuse.
    Wiencek JR; Colby JM; Nichols JH
    Adv Clin Chem; 2017; 80():193-225. PubMed ID: 28431640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations.
    Bush DM
    Forensic Sci Int; 2008 Jan; 174(2-3):111-9. PubMed ID: 17434274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hair analysis by immunological methods from the beginning to 2000.
    Spiehler V
    Forensic Sci Int; 2000 Jan; 107(1-3):249-59. PubMed ID: 10689577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the use of urine, hair, sweat and saliva to detect drug use.
    Dolan K; Rouen D; Kimber J
    Drug Alcohol Rev; 2004 Jun; 23(2):213-7. PubMed ID: 15370028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of drug use during pregnancy.
    Kwong TC; Shearer D
    Obstet Gynecol Clin North Am; 1998 Mar; 25(1):43-64. PubMed ID: 9547759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective Testing: Urine and Other Drug Tests.
    Hadland SE; Levy S
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):549-65. PubMed ID: 27338974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hair analysis for drug detection.
    Kintz P; Villain M; Cirimele V
    Ther Drug Monit; 2006 Jun; 28(3):442-6. PubMed ID: 16778731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.
    Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T
    Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups.
    Lin CN; Nelson GJ; McMillin GA
    J Anal Toxicol; 2013; 37(1):30-6. PubMed ID: 23144203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid urine drug screens: diphenhydramine and methadone cross-reactivity.
    Rogers SC; Pruitt CW; Crouch DJ; Caravati EM
    Pediatr Emerg Care; 2010 Sep; 26(9):665-6. PubMed ID: 20838187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for drugs of abuse: which matrix, oral fluid or urine?
    Allen KR
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):531-41. PubMed ID: 21885472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical issues associated with urine testing of substances of abuse.
    Eskridge KD; Guthrie SK
    Pharmacotherapy; 1997; 17(3):497-510. PubMed ID: 9165553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests.
    Musshoff F; Driever F; Lachenmeier K; Lachenmeier DW; Banger M; Madea B
    Forensic Sci Int; 2006 Jan; 156(2-3):118-23. PubMed ID: 16410161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of point-of-care rapid urine testing for drugs of abuse in the emergency department of an academic medical center: impact on test utilization and ED length of stay.
    Lewandrowski K; Flood J; Finn C; Tannous B; Farris AB; Benzer TI; Lee-Lewandrowski E
    Am J Clin Pathol; 2008 May; 129(5):796-801. PubMed ID: 18426741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exhaled breath for drugs of abuse testing - evaluation in criminal justice settings.
    Beck O
    Sci Justice; 2014 Jan; 54(1):57-60. PubMed ID: 24438778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs of abuse testing in a psychiatric outpatient service.
    Shearer DS; Baciewicz GJ; Kwong TC
    Clin Lab Med; 1998 Dec; 18(4):713-26. PubMed ID: 9891610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable.
    Kranzler HR; Stone J; McLaughlin L
    Drug Alcohol Depend; 1995 Nov; 40(1):55-62. PubMed ID: 8746925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluid testing: new technology enables drug testing without embarrassment.
    Cone EJ
    J Calif Dent Assoc; 2006 Apr; 34(4):311-5. PubMed ID: 16900989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.